Publications by authors named "Ryan L Fleming"
Article Synopsis
- Antibody-drug conjugates (ADCs) are becoming a powerful cancer treatment by specifically delivering toxic drugs into cancer cells through processes that target and degrade the HER2 receptor.
- A bivalent biparatopic antibody that targets two different sites on the HER2 receptor can enhance internalization and degradation, leading to more effective therapy.
- When paired with a microtubule inhibitor, this biparatopic ADC shows improved tumor-fighting results compared to the existing drug ado-trastuzumab emtansine (T-DM1), suggesting it could be a viable treatment option for metastatic breast cancer across various patient groups.
